HWAM
BTAI icon

Hennion & Walsh Asset Management’s BioXcel Therapeutics BTAI Stock Holding History

Hennion & Walsh Asset Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,461
Closed -$14.7K – 873
2024
Q4 		$14.7K Sell
2,461
-45
-2% -$376 ﹤0.01% 851
2024
Q3 		$24.5K Sell
2,506
-31
-1% -$417 ﹤0.01% 866
2024
Q2 		$52K Buy
2,537
+199
+9% +$6.66K ﹤0.01% 838
2024
Q1 		$105K Buy
2,338
+57
+2% +$2.72K 0.01% 831
2023
Q4 		$108K Buy
2,281
+160
+8% +$8.89K 0.01% 810
2023
Q3 		$85.9K Buy
2,121
+1,002
+90% +$101K 0.01% 787
2023
Q2 		$119K Sell
1,119
-1,249
-53% -$416K 0.01% 781
2023
Q1 		$707K Sell
2,368
-81
-3% -$34.6K 0.04% 433
2022
Q4 		$842K Buy
2,449
+310
+14% +$74.9K 0.05% 374
2022
Q3 		$405K Sell
2,139
-30
-1% -$6.96K 0.03% 531
2022
Q2 		$458K Sell
2,169
-32
-1% -$6.73K 0.03% 506
2022
Q1 		$736K Buy
2,201
+45
+2% +$13K 0.04% 419
2021
Q4 		$701K Buy
2,156
+134
+7% +$57.5K 0.03% 450
2021
Q3 		$982K Buy
2,022
+693
+52% +$305K 0.05% 356
2021
Q2 		$618K Buy
+1,329
New +$724K 0.03% 476

Other funds holding BTAI

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Hennion & Walsh Asset Management's BTAI Position: Q1 2025 in Review

Hennion & Walsh Asset Management sold out of BioXcel Therapeutics (BTAI) in Q1 2025, closing a stake of 2,461 shares — an estimated $14.7K sold.

Hennion & Walsh Asset Management first reported a position in BTAI in Q2 2021 and held it in 15 quarters. The position peaked at $982K in Q3 2021. 31 funds tracked by Wall St. Rank hold BTAI as of Q1 2025.

  • Hennion & Walsh Asset Management reported no remaining BioXcel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 2,461 BioXcel Therapeutics shares in Q1 2025, an estimated $14.7K.
  • Hennion & Walsh Asset Management first reported a position in BioXcel Therapeutics in Q2 2021 and held it in 15 quarters.
  • Hennion & Walsh Asset Management's BioXcel Therapeutics position peaked at $982K in Q3 2021.
  • 31 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2025.

Based on Hennion & Walsh Asset Management's 13F filing for Q1 2025, filed 10 Apr 2025.